Patient Page

▶

▶

▶

Tolvaptan (JINARC^®) is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with chronic kidney disease (CKD) at initiation of treatment with evidence of rapidly progressing disease.
It has not been determined whether Tolvaptan (JINARC^®) is both safe & effective for children.

Do not take Tolvaptan (JINARC^®) if you:

have a history of liver problems*

*This excludes those with polycystic liver disease who have liver problems.

have high or low sodium levels

are allergic to Tolvaptan

cannot feel thirst or unable to drink

are dehydrated

are unable to urinate

Once prescribed, patients can call the ADPKD hotline to inquire and enroll in the mandatory safety monitoring program (Jinarc^® RMP)

Requirements:

Updated Tolvaptan (Jinarc^®) prescription*
Updated Liver Function Test (LFT) results*
1. ✓ SGPT/ALT
2. ✓ SGOT/AST
3. ✓ Bilirubin
*must be updated (dated within the last 30 days)